Siegfried Holding AG
SIX:SFZN

Watchlist Manager
Siegfried Holding AG Logo
Siegfried Holding AG
SIX:SFZN
Watchlist
Price: 979 CHF -0.2%
Market Cap: 4.4B CHF
Have any thoughts about
Siegfried Holding AG?
Write Note

Siegfried Holding AG
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Siegfried Holding AG
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Siegfried Holding AG
SIX:SFZN
Accounts Receivables
CHf355.2m
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Accounts Receivables
CHf136m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
15%
Lonza Group AG
SIX:LONN
Accounts Receivables
CHf1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Tecan Group AG
SIX:TECN
Accounts Receivables
CHf183m
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Accounts Receivables
€78.8m
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Accounts Receivables
CHf26.5m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Siegfried Holding AG
Glance View

Market Cap
4.2B CHF
Industry
Life Sciences Tools & Services

Nestled in the picturesque landscapes of Zofingen, Switzerland, Siegfried Holding AG operates as a key player in the global pharmaceutical supply chain, crafting a narrative of innovation and precision. With roots tracing back to 1873, this stalwart company has evolved over the decades, now standing as a leading supplier of active pharmaceutical ingredients (APIs) and finished dosage forms to the pharmaceutical industry. Siegfried's operations are defined by a seamless integration of chemistry and technology, embodying Swiss precision in every facet of its production process. The company's trajectory is marked by strategic expansions and acquisitions, allowing it to amass a presence in both Europe and North America, crafting a network that ensures its reliability and reach. At the heart of Siegfried's success lies its business model, a symbiotic partnership with pharmaceutical companies that rely on its vast expertise to bring their products to market. Siegfried essentially straddles both ends of the pharmaceutical value chain, deriving revenue by providing essential APIs as well as a robust offering of finished drugs. The company excels in tailor-made solutions, offering complex manufacturing processes that meet stringent regulatory demands. This dual capability not only diversifies its revenue streams but also buffers it against the volatile dynamics of the pharmaceutical industry. With a focus on quality and customer-centric innovation, Siegfried continues to carve a niche as a trusted collaborator, underpinning the development of health solutions worldwide.

SFZN Intrinsic Value
1 168.32 CHF
Undervaluation 16%
Intrinsic Value
Price

See Also

What is Siegfried Holding AG's Accounts Receivables?
Accounts Receivables
355.2m CHF

Based on the financial report for Jun 30, 2024, Siegfried Holding AG's Accounts Receivables amounts to 355.2m CHF.

What is Siegfried Holding AG's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
15%

Over the last year, the Accounts Receivables growth was 11%. The average annual Accounts Receivables growth rates for Siegfried Holding AG have been 17% over the past three years , 15% over the past five years .

Back to Top